|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Melanoma | |||||
| Metastases | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Neoplasm Metastasis | |||||
| 3 | More general conditions related to this trial | ||||
| Neoplasms | |||||
| Neoplasms by Histologic Type | |||||
| Neoplasms, Germ Cell and Embryonal | |||||
| Neoplasms, Nerve Tissue | |||||
| Neoplastic Processes | |||||
| Neuroectodermal Tumors | |||||
| Neuroendocrine Tumors | |||||
| Nevi and Melanomas | |||||
| Pathologic Processes | |||||
| 4 | Interventions listed in this trial | ||||
| MDX-1379 Melanoma Peptide Vaccine | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Antibodies | |||||
| Antibodies, Monoclonal | |||||
| 6 | More general drug interventions related to this trial | ||||
| Immunologic Factors | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| 7 | Sponsors listed in this trial | ||||
| Medarex | |||||